Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians.
Decisions regarding the use of adjuvant cytotoxic and hormonal therapies for women with breast cancer ideally should be made jointly by the patient and oncologist. For patients to be adequately involved in this decision-making process, they must be provided with appropriate education regarding the potential benefits and risks of adjuvant therapies. The recommended steps for doing this are: 1) understand baseline prognosis with locoregional therapy (surgery, radiation, or both) alone for the individual patient at hand; 2) determine the estimated benefit afforded by adjuvant therapy options for the individual patient; 3) estimate the risk of side effects of adjuvant therapy options; 4) convey the above information to the individual patient; 5) facilitate the individual patient's decision regarding adjuvant systemic therapy; and 6) support the patient's decision. Two computer-based tools (Numeracy and Adjuvant!) are available to facilitate this process.
Loprinzi
Charles L
CL
Mayo Clinic, Rochester, Minnesota 550905, USA. cloprinzi@mayo.edu
Ravdin
Peter M
PM
D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D003658:Decision Making, Computer-Assisted; D003661:Decision Support Techniques; D005260:Female; D006801:Humans; D010342:Patient Acceptance of Health Care; D017410:Practice Guidelines as Topic
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal